Emmaus Life Sciences said last week that the FDA approved its L-glutamine oral powder, Endari, as a therapy to lessen the complications of sickle cell disease in patients ages 5 and older.
The drug’s approval was supported by data from a Phase III trial evaluating Endari compared to a placebo in 230 adults and children with sickle cell disease. The data showed that Endari cut the frequency of sickle cell crises by one-fourth and hospitalizations by 33%, according to Emmaus.
Get the full story at our sister site, Drug Delivery Business News.